Chief Medical Officer Hetal Kocinsky departs; Andrew King to lead clinical programs

Jade Biosciences, Inc.

Hetal Kocinsky, M.D., left CMO role effective Sept 9, 2025.
Company expects separation agreement: 12 months base salary plus 12 months COBRA premium payment.
Dr. Andrew King, Ph.D, CSO & Head of R&D, will continue leading scientific and clinical programs.
No successor named for CMO role; no details on search process.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.